In connection with the Carisma transaction, the Sesen Bio Board of Directors has declared a one-time, special cash dividend of $75M. Based on the current number of shares outstanding, the special cash dividend is expected to result in 36.1c per share to all common stockholders of record as of the close of business on March 7, 2023, payable no later than March 10, 2023. Sesen Bio stockholders of record will also be issued one Contingent Value Right for each outstanding share of Sesen Bio common stock, representing the right to receive any potential proceeds from the sale of Vicineum and Sesen Bio’s preclinical assets prior to March 31, 2027 and any proceeds from the potential milestone payment under the Roche Asset Purchase Agreement. The issuance of the special cash dividend and CVR remain contingent on the closing of the approved transaction.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SESN:
- Sesen Bio reports Q4 EPS (4c), consensus (11c)
- Sesen Bio announces Glass Lewis recommendation to vote for merger with Carisma
- Sesen Bio boosts special cash dividend to 36c per share, Torok to join board
- Sesen Bio gets Nasdaq delisting notice, company sees Carisma deal as viable path
- Sesen Bio: Pending Carisma merger in best interests of stockholders